ERBB2 and non-small cell lung carcinoma: The safety and efficacy of allitinib are currently being evaluated in a phase II study (CTR20150258; PI: Yi-long Wu, Guangdong General Hospital, China) on patients with advanced HER2-positive NSCLC for whom previous chemotherapy failed.